AGS-1C4D4 + Gemcitabine
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Pancreatic Ductal
Conditions
Carcinoma, Pancreatic Ductal, Pancreatic Cancer, Pancreatic Disease
Trial Timeline
Apr 1, 2009 → Apr 1, 2012
NCT ID
NCT00902291About AGS-1C4D4 + Gemcitabine
AGS-1C4D4 + Gemcitabine is a phase 2 stage product being developed by Astellas Pharma for Carcinoma, Pancreatic Ductal. The current trial status is completed. This product is registered under clinical trial identifier NCT00902291. Target conditions include Carcinoma, Pancreatic Ductal, Pancreatic Cancer, Pancreatic Disease.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Pancreatic Ductal were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01608711 | Phase 2 | Completed |
| NCT00902291 | Phase 2 | Completed |
Competing Products
20 competing products in Carcinoma, Pancreatic Ductal